Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Nature · 897 citations
https://doi.org/10.1038/s41586-018-0810-y
M
Manja Idorn
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
70
Papers
4.0K
Citations
25
h-index
36
i10-index
Manja Idorn is an academic researcher from Aarhus University. The author has contributed to research in topics: Immunotherapy and Immune Responses & SARS-CoV-2 and COVID-19 Research & CAR-T cell therapy research. The author has an h-index of 25, co-authored 60 publications.
ORCID: 0000-0002-6769-9165Papers by this author
worksSARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate
2020 · Nature Communications · 450 citations
https://doi.org/10.1038/s41467-020-18764-3
Exercise and cancer: from “healthy” to “therapeutic”?
2017 · Cancer Immunology Immunotherapy · 152 citations
https://doi.org/10.1007/s00262-017-1985-z
Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1
2022 · EMBO Reports · 77 citations
https://doi.org/10.15252/embr.202255839
Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate
2020 · Nature Communications · 31 citations
https://doi.org/10.1038/s41467-020-19363-y
Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro
2020 · Antiviral Research · 27 citations
https://doi.org/10.1016/j.antiviral.2020.104988
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat